Abstract：Objective: To investigate the effect of Astragalus membranaceus on inflammatory factors and cellular immunity of viral myocarditis patients. Methods: 70 children with viral myocarditis hospitalized in our hospital from April 2016 to March 2018 were selected as the study subjects. According to the random number table method, they were divided into study group (38 cases) and control group (32 cases).The control group received conventional treatment, while the study group continued to use astragalus on the basis of the former.The clinical efficacy, inflammatory factors (TNF-alpha, il-6, il-17) and cellular immunity of the two groups were compared before and after treatment.To evaluate the clinical value of astragalus in children with viral myocarditis. Results: The total effective rate in the study group (89.47%) was greater than that in the control group (68.75%) (χ2 =4.663, P<0.05). Repeated measurement analysis of variance showed that the time point, group, time point and interaction effect of CK, CK-MB, LD, cTnI, TNF - α, IL-6, IL-17, CD3 +, CD4 +, CD4 + / CD8 + levels in the two groups were statistically significant (P<0.05), and the levels of CK, CK-MB, LD, cTnI, TNF - α, IL-6, IL-17 in the study group were lower than those in the control group at 1 or 2 weeks after treatment. The levels of CD3 +, CD4 +, CD4 + / CD8 + were significantly higher than those of the control group (P<0.05). Conclusion: Astragalus membranaceus has a significant effect on children with viral myocarditis. It can effectively improve the immune function of children, reduce the incidence of inflammation, and has a positive significance for the recovery of children after treatment.
[1] Hao L , Bate H , Ying X , et al. Effects of total flavonids of astragalus on arrhythmia,endoplasmic reticulum stress in mice with viral myocarditis[J]. Chinese Journal of Applied Physiology, 2018, 34(1):16. [2] Lisa,Kraft,Tugs,Erdenesukh,et al.Blocking the IL-1β signalling pathway prevents chronic viral myocarditis and cardiac remodeling.[J].Basic Research in Cardiology,2019,114(2):11. [3] 金智利.黄芪注射液治疗小儿病毒性心肌炎疗效分析[J].临床医药文献电子杂志,2019,6(38):69. [4] 王利民.黄芪注射液治疗病毒性心肌炎对患者心肌肌钙蛋白Ⅰ和心肌酶指标的影响[J].医药论坛杂志,2017,38(9):155~156. [5] 李波,张亚群,左婷.黄芪注射液对慢阻肺患者气道重塑及纤维化相关指标的影响[J].实用临床医药杂志,2017,21(9):165~167. [6] 李琳,李宁宁,邓丽萍.黄芪注射液治疗小儿病毒性心肌炎的疗效[J].中国民康医学,2019,31(2):61~63. [7] 马战胜.黄芪注射液对病毒性心肌炎患者心肌胶原重构及心肌损伤相关血清指标的影响[J].临床心身疾病杂志,2017,23(5):106~109. [8] 胡晓光,齐冰.黄芪注射液联合参麦注射液治疗小儿病毒性心肌炎及对心肌酶、细胞因子的影响[J].海峡药学,2018,30(10):131~133. [9] 牛方卿,朱立杰,杨宏辉.黄芪注射液联合牛磺酸对急性病毒性心肌炎患者免疫功能的影响[J].世界中医药,2019,14(5):1242~1245,1250. [10] 江志泳,朱海燕.益气解毒护心汤治疗邪毒侵心型病毒性心肌炎的临床疗效及对血清心肌酶谱指标的影响[J].四川中医,2018,36(2):82~84. [11] 刘德志,兰作发.黄芪注射液辅助治疗对小儿病毒性心肌炎的临效及对心肌损伤、免疫功能、炎症反应的影响[J].现代实用医学,2018,30(1):95~97. [12] 杨兵,林爱琴,罗晓华,等.不同严重程度冠心病患者外周血Treg和Th17细胞的测定[J].郑州大学学报(医学版),2018,53(5):658~661.
2020, Vol. 26 
冀公网安备13080202000677号